UPDATED RESULTS FROM THE CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA SZ Usmani, JG Berdeja, A Jakubowiak, M Agha, AD Cohen, D Madduri, P Hari, T Yeh, Y Olyslager, A Banerjee, CC Jackson, A Allred, E Zudaire, W Deraedt, X Wu, L Pacaud, M Akram, Y Lin, T Martin, S Jagannath

EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA M Solh, NJ Bahlis, NS Raje, CL Costello, B Dholaria, MY Levy, MH Tomasson, H Dube, MA Damore, HK Lon, C Basu, A Skoura, EM Chan, S Trudel, A Jakubowiak, MP Chu, C Gasparetto, A Dalovisio, M Sebag, AM Lesokhin

EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER 1–3 PRIOR LINES OF THERAPY: CARTITUDE-2 PHASE 2 STUDY ME Agha, AD Cohen, D Madduri, YC Cohen, M Delforge, J Hillengass, H Goldschmidt, K Weisel, M Raab, C Scheid, JM Schecter, KC Braganca, H Varsos, L Wang, M Vogel, MJ Carrasco-Alfonso, M Akram, X Wu, T Nesheiwat, H Einsele